Sofia A Pereira

List of Publications by Year in Descending Order

62 papers	735 citations	17 h-index	23 g-index
85 ext. papers	1,015 ext. citations	4.9 avg, IF	4.26 L-index

#	Paper	IF	Citations
62	Circulating (poly)phenol Metabolites: Neuroprotection in a 3D Cell Model of Parkinson's Disease.. *Molecular Nutrition and Food Research*, **2021**, e2100959	5.9	0
61	The 2-hydroxy-nevirapine metabolite as a candidate for boosting apolipoprotein A1 and for modulating anti-HDL antibodies. *Pharmacological Research*, **2021**, 165, 105446	10.2	
60	Anti-Angiogenic Therapy: Current Challenges and Future Perspectives. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	23
59	A simple method to measure sulfonation in man using paracetamol as probe drug. *Scientific Reports* , **2021**, 11, 9036	4.9	0
58	ARYL HYDROCARBON RECEPTOR ANTAGONISTS - A NEW ENTRY IN ANTIHYPERTENSIVE ARMAMENTARIUM OF OBSTRUCTIVE SLEEP APNEA?. *Journal of Hypertension*, **2021**, 39, e255-e256	1.9	
57	The Activation of Endothelial Cells Relies on a Ferroptosis-Like Mechanism: Novel Perspectives in Management of Angiogenesis and Cancer Therapy. *Frontiers in Oncology*, **2021**, 11, 656229	5.3	6
56	Cysteine metabolic circuitries: druggable targets in cancer. *British Journal of Cancer*, **2021**, 124, 862-879	8.7	23
55	Electrochemical Activity of Cytochrome P450 1A2: The Relevance of O2 Control and the Natural Electron Donor. *ChemElectroChem*, **2021**, 8, 500-507	4.3	0
54	Electrochemical Activity of Cytochrome P450 1A2: The Relevance of O2 Control and the Natural Electron Donor. *ChemElectroChem*, **2021**, 8, 430-430	4.3	
53	AHR canonical pathway: in vivo findings to support novel antihypertensive strategies. *Pharmacological Research*, **2021**, 165, 105407	10.2	3
52	Cysteine Boosts Fitness Under Hypoxia-Mimicked Conditions in Ovarian Cancer by Metabolic Reprogramming. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 722412	5.7	4
51	Aryl Hydrocarbon Receptor and Cysteine Redox Dynamics Underlie (Mal)adaptive Mechanisms to Chronic Intermittent Hypoxia in Kidney Cortex. *Antioxidants*, **2021**, 10,	7.1	1
50	A Mechanistic-Based and Non-invasive Approach to Quantify the Capability of Kidney to Detoxify Cysteine-Disulfides. *Advances in Experimental Medicine and Biology*, **2021**, 1306, 109-120	3.6	1
49	Nevirapine Biotransformation Insights: An Integrated In Vitro Approach Unveils the Biocompetence and Profile of a Human Hepatocyte-Like Cell 3D Model. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	6
48	Berry fruits modulate kidney dysfunction and urine metabolome in Dahl salt-sensitive rats. *Free Radical Biology and Medicine*, **2020**, 154, 119-131	7.8	5
47	First evidence of aryl hydrocarbon receptor as a druggable target in hypertension induced by chronic intermittent hypoxia. *Pharmacological Research*, **2020**, 159, 104869	10.2	4
46	Monocytes as Endothelial Progenitor Cells (EPCs), Another Brick in the Wall to Disentangle Tumor Angiogenesis. *Cells*, **2020**, 9,	7.9	12

45	F13. PLATELET-LYMPHOCYTE RATIO AS A SHORT-TERM TREATMENT-RESPONSE PREDICTOR IN SCHIZOPHRENIA RELAPSE. *Schizophrenia Bulletin*, **2019**, 45, S258-S259	1.3	78
44	The mercapturomic profile of health and non-communicable diseases. *High-Throughput*, **2019**, 8,	4.3	4
43	Mass Spectrometry-Based Methodologies for Targeted and Untargeted Identification of Protein Covalent Adducts (Adductomics): Current Status and Challenges. *High-Throughput*, **2019**, 8,	4.3	9
42	Changes in N-acetyltransferase 8 in kidney tubular cell: injury, recovery and mesenchymal stromal cell-based therapy **2019**,		1
41	Targeting Glutathione and Cystathionine Synthase in Ovarian Cancer Treatment by Selenium-Chrysin Polyurea Dendrimer Nanoformulation. *Nutrients*, **2019**, 11,	6.7	20
40	Singularities of nevirapine metabolism: from sex-dependent differences to idiosyncratic toxicity. *Drug Metabolism Reviews*, **2019**, 51, 76-90	7	7
39	Mercapturate Pathway in the Tubulocentric Perspective of Diabetic Kidney Disease. *Nephron*, **2019**, 143, 17-23	3.3	12
38	Anti-tumorigenic and Platinum-Sensitizing Effects of Apolipoprotein A1 and Apolipoprotein A1 Mimetic Peptides in Ovarian Cancer. *Frontiers in Pharmacology*, **2018**, 9, 1524	5.6	9
37	High resolution mass spectrometry-based methodologies for identification of Etravirine bioactivation to reactive metabolites: In vitro and in vivo approaches. *European Journal of Pharmaceutical Sciences*, **2018**, 119, 70-82	5.1	8
36	Usefulness of zebrafish larvae to evaluate drug-induced functional and morphological renal tubular alterations. *Archives of Toxicology*, **2018**, 92, 411-423	5.8	22
35	Cysteine boosters the evolutionary adaptation to CoCl mimicked hypoxia conditions, favouring carboplatin resistance in ovarian cancer. *BMC Evolutionary Biology*, **2018**, 18, 97	3	14
34	Zebrafish Larvae Are a Suitable Model to Investigate the Metabolic Phenotype of Drug-Induced Renal Tubular Injury. *Frontiers in Pharmacology*, **2018**, 9, 1193	5.6	8
33	The first-line antiepileptic drug carbamazepine: Reaction with biologically relevant free radicals. *Free Radical Biology and Medicine*, **2018**, 129, 559-568	7.8	6
32	Cysteine Oxidative Dynamics Underlies Hypertension and Kidney Dysfunction Induced by Chronic Intermittent Hypoxia. *Advances in Experimental Medicine and Biology*, **2018**, 1071, 83-88	3.6	8
31	Improvement of neuronal differentiation by carbon monoxide: Role of pentose phosphate pathway. *Redox Biology*, **2018**, 17, 338-347	11.3	14
30	Cysteine allows ovarian cancer cells to adapt to hypoxia and to escape from carboplatin cytotoxicity. *Scientific Reports*, **2018**, 8, 9513	4.9	31
29	Implications of sulfotransferase activity in interindividual variability in drug response: clinical perspective on current knowledge. *Drug Metabolism Reviews*, **2017**, 49, 357-371	7	18
28	Hepatocyte spheroids as a competent in vitro system for drug biotransformation studies: nevirapine as a bioactivation case study. *Archives of Toxicology*, **2017**, 91, 1199-1211	5.8	19

27	Unmasking efavirenz neurotoxicity: Time matters to the underlying mechanisms. *European Journal of Pharmaceutical Sciences*, **2017**, 105, 47-54	5.1	18
26	Efavirenz biotransformation as an up-stream event of mood changes in HIV-infected patients. *Toxicology Letters*, **2016**, 260, 28-35	4.4	5
25	Assessment of human paraoxonase activity by electrochemistry: a simple and novel approach. *Analytical Methods*, **2016**, 8, 8141-8146	3.2	1
24	Nevirapine modulation of paraoxonase-1 in the liver: An in vitro three-model approach. *European Journal of Pharmaceutical Sciences*, **2016**, 82, 147-53	5.1	6
23	HNF1 drives glutathione (GSH) synthesis underlying intrinsic carboplatin resistance of ovarian clear cell carcinoma (OCCC). *Tumor Biology*, **2016**, 37, 4813-29	2.9	34
22	Sex differences in hepatic and intestinal contributions to nevirapine biotransformation in rats. *Chemico-Biological Interactions*, **2015**, 233, 115-21	5	4
21	Efficacy of carvedilol in reversing hypertension induced by chronic intermittent hypoxia in rats. *European Journal of Pharmacology*, **2015**, 765, 58-67	5.3	13
20	Quinoid derivatives of the nevirapine metabolites 2-hydroxy- and 3-hydroxy-nevirapine: activation pathway to amino acid adducts. *Toxicology Research*, **2015**, 4, 1565-1577	2.6	3
19	Voluntary Oral Administration of Losartan in Rats. *Journal of the American Association for Laboratory Animal Science*, **2015**, 54, 549-56	1.3	14
18	Bioactivation to an aldehyde metabolite--possible role in the onset of toxicity induced by the anti-HIV drug abacavir. *Toxicology Letters*, **2014**, 224, 416-23	4.4	18
17	Differences in nevirapine biotransformation as a factor for its sex-dependent dimorphic profile of adverse drug reactions. *Journal of Antimicrobial Chemotherapy*, **2014**, 69, 476-82	5.1	18
16	Quantification of the arylesterase activity of paraoxonase-1 in human blood. *Analytical Methods*, **2014**, 6, 289-294	3.2	10
15	Development and validation of an HPLC-UV method for quantifying nevirapine and its main phase I metabolites in human blood. *Analytical Methods*, **2014**, 6, 1575	3.2	7
14	Sex differences in apolipoprotein A1 and nevirapine-induced toxicity. *Journal of the International AIDS Society*, **2014**, 17, 19575	5.4	2
13	Monitoring of the lactonase activity of paraoxonase-1 enzyme in HIV-1-infection. *Journal of the International AIDS Society*, **2014**, 17, 19682	5.4	3
12	Monitoring abacavir bioactivation in humans: screening for an aldehyde metabolite. *Toxicology Letters*, **2013**, 219, 59-64	4.4	17
11	The role of competitive binding to human serum albumin on efavirenz-warfarin interaction: a nuclear magnetic resonance study. *International Journal of Antimicrobial Agents*, **2013**, 42, 443-6	14.3	10
10	Development and validation of an assay for the simultaneous determination of zidovudine, abacavir, emtricitabine, lamivudine, tenofovir and ribavirin in human plasma using liquid chromatography-tandem mass spectrometry. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2013**, 919-920, 43-51	3.2	25

9	Long-term maraviroc use as salvage therapy in HIV-2 infection. *Journal of Antimicrobial Chemotherapy*, **2012**, 67, 2538-9	5.1	12
8	N-terminal valine adduct from the anti-HIV drug abacavir in rat haemoglobin as evidence for abacavir metabolism to a reactive aldehyde in vivo. *British Journal of Pharmacology*, **2012**, 167, 1353-61	8.6	14
7	Evidence for nevirapine bioactivation in man: searching for the first step in the mechanism of nevirapine toxicity. *Toxicology*, **2012**, 301, 33-9	4.4	31
6	Insights into the Role of Bioactivation Mechanisms in the Toxic Events Elicited by Non-nucleoside Reverse Transcriptase Inhibitors. *Advances in Molecular Toxicology*, **2012**, 6, 1-39	0.4	3
5	Reactive aldehyde metabolites from the anti-HIV drug abacavir: amino acid adducts as possible factors in abacavir toxicity. *Chemical Research in Toxicology*, **2011**, 24, 2129-41	4	26
4	Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients. *British Journal of Clinical Pharmacology*, **2009**, 68, 891-7	3.8	8
3	Efavirenz concentrations in HIV-infected patients with and without viral hepatitis. *British Journal of Clinical Pharmacology*, **2008**, 66, 551-5	3.8	13
2	Intra-individual variability in efavirenz plasma concentrations supports therapeutic drug monitoring based on quarterly sampling in the first year of therapy. *Therapeutic Drug Monitoring*, **2008**, 30, 60-6	3.2	22
1	Long-term and concentration-dependent beneficial effect of efavirenz on HDL-cholesterol in HIV-infected patients. *British Journal of Clinical Pharmacology*, **2006**, 61, 601-4	3.8	19